UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT Pursuant
to Section 13 or 15(d)
of the
Securities Exchange Act
of 1934
Date of report (Date of earliest event reported): June 13, 2005
Integrated BioPharma,
Inc.
(Exact Name of Registrant as Specified in Its Charter)
Delaware
(State or Other
Jurisdiction of Incorporation)
| 000-28876 | 22-2407475 | |
| (Commission File Number) | (IRS Employer Identification No.) | |
| 225 Long Avenue | ||
| Hillside, New Jersey | 07205 | |
| (Address of Principal Executive Offices) | (Zip Code) | |
| (973) 926-0816 | ||
| (Registrant’s Telephone Number, Including Area Code) | ||
|
(Former Name or Former Address, if Changed Since Last Report) |
||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| |_| | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |_| | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |_| | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |_| | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 7.01. Regulation FD Disclosure
On June 13, 2005, Integrated BioPharma, Inc. released an investor relations presentation. The document is attached as an exhibit to this Report.Item 9.01. Financial Statements and Exhibits
(c) Exhibits.
Exhibit No. Description
99.1 Investor Relations Presentation issued by Integrated BioPharma, Inc. on June 13, 2005.
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.
INTEGRATED BIOPHARMA, INC.